UPDATE: Piper Sandler Starts Sight Sciences Inc. (SGHT) at Overweight

Piper Sandler analyst Matt O'Brien initiates coverage on Sight Sciences Inc. (NASDAQ: SGHT) with a Overweight rating and a price target of $44.00.

The analyst comments "We are initiating coverage of SGHT with an OW rating and $44 price target. The company’s unique Omni technology for treating glaucoma addresses a $9B market opportunity globally. With only one of two labels to treat the largest segment of this market (standalone patients), we see a long runway for revenue growth over the next several years. Augmenting that top-line outlook, in a few years, should be a bigger contribution from the company’s TearCare product. Collectively, we anticipate SGHT will deliver some of the most robust revenue growth in the coming years, elevating the scarcity value of the name."

For an analyst ratings summary and ratings history on Sight Sciences Inc. click here. For more ratings news on Sight Sciences Inc. click here.

Shares of Sight Sciences Inc. closed at $37.29 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• SoundThinking (SSTI) PT Lowered to $8 at Cantor Fitzgerald